IN2012DN00549A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00549A
IN2012DN00549A IN549DEN2012A IN2012DN00549A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A IN 549DEN2012 A IN549DEN2012 A IN 549DEN2012A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A
Authority
IN
India
Prior art keywords
subject
activity
relates
compounds
hif levels
Prior art date
Application number
Other languages
English (en)
Inventor
Kang Xinshan
Long Wei
Ma Cunbo
Wang Yanping
Cao Hong
Wang Yinxiang
Tan Fenlai
Hu Yunyan
Original Assignee
Zhejiang Beta Pharma Inc
Kang Xinshan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc, Kang Xinshan filed Critical Zhejiang Beta Pharma Inc
Publication of IN2012DN00549A publication Critical patent/IN2012DN00549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN549DEN2012 2009-07-15 2010-07-14 IN2012DN00549A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910089274 2009-07-15
PCT/CN2010/001057 WO2011006355A1 (en) 2009-07-15 2010-07-14 Compounds as hypoxia mimetics, and compositions, and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00549A true IN2012DN00549A (enExample) 2015-06-12

Family

ID=43448908

Family Applications (1)

Application Number Title Priority Date Filing Date
IN549DEN2012 IN2012DN00549A (enExample) 2009-07-15 2010-07-14

Country Status (13)

Country Link
US (1) US8742138B2 (enExample)
EP (1) EP2454249B1 (enExample)
JP (1) JP5847710B2 (enExample)
KR (1) KR20120065311A (enExample)
CN (1) CN102164905B (enExample)
AU (1) AU2010273101B2 (enExample)
CA (1) CA2767911C (enExample)
ES (1) ES2702524T3 (enExample)
IL (1) IL217531A0 (enExample)
IN (1) IN2012DN00549A (enExample)
SG (1) SG177598A1 (enExample)
WO (1) WO2011006355A1 (enExample)
ZA (1) ZA201200293B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2736892A4 (en) * 2011-07-29 2015-03-18 Beijing Betta Pharmaceuticals Co Ltd STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF
CA2959688C (en) 2014-09-02 2024-02-27 Sunshine Lake Pharma Co., Ltd. Quinolone compounds and their use to treat diseases related to hypoxia inducible factor and/or erythropoietin
US20160193238A1 (en) * 2015-01-05 2016-07-07 National Cancer Center HNF4-alpha ANTAGONIST AND USE THEREOF
US10450569B2 (en) 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
JP7142406B2 (ja) 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080649A2 (en) 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
CA2618770A1 (en) * 2005-08-25 2007-03-01 Emory University Hif inhibitors
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
PE20071020A1 (es) * 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
AR066691A1 (es) * 2007-03-29 2009-09-09 Speedel Experimenta Ag Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.
US8324405B2 (en) * 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
WO2010024908A1 (en) * 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for treatment of multiple sclerosis

Also Published As

Publication number Publication date
JP5847710B2 (ja) 2016-01-27
HK1161234A1 (en) 2012-08-24
US8742138B2 (en) 2014-06-03
EP2454249B1 (en) 2018-09-19
JP2012532897A (ja) 2012-12-20
CN102164905B (zh) 2014-04-30
AU2010273101B2 (en) 2016-02-25
ES2702524T3 (es) 2019-03-01
US20120172399A1 (en) 2012-07-05
EP2454249A1 (en) 2012-05-23
CA2767911C (en) 2016-03-29
CN102164905A (zh) 2011-08-24
SG177598A1 (en) 2012-02-28
KR20120065311A (ko) 2012-06-20
CA2767911A1 (en) 2011-01-20
EP2454249A4 (en) 2012-12-12
AU2010273101A1 (en) 2012-02-02
ZA201200293B (en) 2012-09-26
AU2010273101A2 (en) 2012-03-15
IL217531A0 (en) 2012-02-29
WO2011006355A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
IN2012DN00624A (enExample)
IN2015DN00438A (enExample)
IN2014DN09782A (enExample)
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
IN2014DN05986A (enExample)
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
TW201611843A (en) Methods of treatment with arginine deiminase
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
GB2482817A (en) Novel use
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MY173722A (en) Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
EA201390876A1 (ru) Соединения, ингибирующие металлоферменты
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
NZ705406A (en) Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis